- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02472054
Treatment of Familiar Lymphohistiocytosis (C-HLH)
First Line Treatment of Familiar Lymphohistiocytosis by Alemtuzumab (CAMPATH®)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The hemophagocytic lymphohistiocytosis (HLH) or lymphohistiocytic activation syndrome is an inflammatory condition caused by a uncontrolled proliferation of activated lymphocytes and macrophages secreting an excess of inflammatory cytokines. Familial hemophagocytic lymphohistiocytosis (FHL) is a rare disorder of the immune system, which is invariably fatal when untreated. Treatment requires the achievement of remission of HLH prior to allogeneic hematopoietic stem cell transplantation, the only curative therapy to date.
Despite significant progress in the treatment, mortality remains high and an important number of patients will die before being eligible for HSCT.
A better understanding of the pathophysiology of FHL has opened new avenues for immunotherapy. Based on previous observations concerning the utilization of Anti-thymoglobulins (ATG) for the treatment of patients with FHL, the protocol propose a new therapeutic strategy using Alemtuzumab in association with steroids as first line treatment in FHL. This proposition is based on the hypothesis that Alemtuzumab, capable of killing T lymphocytes efficiently in vivo, should be better tolerated than ATG. In fact, in contrast to the mechanism of action of ATG, Alemtuzumab does not activate T lymphocytes.
A better tolerance and efficacy of Alemtuzumab is expected in the treatment of the hemophagocytic lymphohistiocytic syndrome. This may have a positive impact not only on survival until HSCT, but also on overall survival and quality of life with regard to long-term neurological sequelae.
This is a multicenter, open, phase I/II, non-comparative, non randomized study. Patients are recruited by the investigators during hospitalization for a first episode of lymphohistiocytic activation syndrome requiring specific treatment.
Several visits (including the final visit) are scheduled within the trial over a period of approximately 10 months for all patients, from the signature of the consent up to 6 months after hematopoietic stem cell transplantation.
The recruitment period will be 48 months; the total period of the study is 58 months. The treatment consists in an intravenous administration of CAMPATH®.
For the research purpose, investigators will collect specific samples for:
- biobank (Cytokine dosage) at the inclusion visit and the day prior to the conditioning;
- pharmacokinetics of CAMPATH® : at every cure of CAMPATH® and every week. Also diagnostic lumbar puncture at the inclusion visit, day 14 is required to document the response to treatment and to determine the result of the therapeutic care.
The efficacy of the treatment will be measured to Day14, Day21 and Day28. All adverse events must be reported in the e-Case Report Form (e-CRF)
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75015
- Hôpital Necker-Enfants Malades
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria :
- Patient < 18 years
Patient with diagnosis of hemophagocytic lymphohistiocytic syndrome confirmed by at least one of the following two criteria :
- Genetic diagnosis FHL or other genetic disease predisposing to HLH like Chediak-Higashi syndrome, Griscelli syndrome type II and X-linked lymphoproliferative syndrome type I and II (XLP-1 and XLP-2) or positive family history of HLH
- Presence of at least 5 of the following 8 criteria (diagnostic criteria as defined by the "Histiocyte Society" ) :
- Fever
- Splenomegaly
- Cytopenia (affecting at least two cell lineages : Hemoglobin <9.0 g / dl, Platelets <100.000/μl, Absolute neutrophil count (ANC) <1.000/µl)
- Hypertriglyceridemia and / or hypofibrinogenemia (Fasting triglycerides ≥ 3 mmol / l, Fibrinogen ≤ 1.5 g / l)
- Haemophagocytosis found in a histological specimen (without evidence of a malignant process and rheumatic disease)
- Decreased or absent NK function (<10% of the laboratory standard)
- Ferritin ≥ 500μg / l
- Soluble CD25 ≥ 2.400U/ml or presence of activated T cells in the immune phenotyping
- Patient without prior specific treatment of lymphohistiocytic activation syndrome or under treatment with corticosteroids and / or ciclosporin.
- Patient beneficiary of a health insurance scheme
- Holder (s) of parental authority who signed the informed consent
- Man or woman in reproductive age willing to take reliable contraceptive measures during the treatment and 6 months after the end of the treatment
Specific situation of patients with neurological involvement :
Most patients with neurological involvement caused by a HLH will meet the inclusion criteria. However some patients may present an isolated neurological involvement as the first manifestation of familiar lymphohistiocytosis as described in the literature. These patients do not always present all the inclusion criteria. However their clinical condition may justify their inclusion prior to the confirmation of a genetic diagnosis and/or the detection of all required diagnostic inclusion criteria.
In the absence of the required 5 out of 8 diagnostic criteria, the eventual inclusion of patients with predominant neurological involvement will be evaluated by a scientific committee to judge their inclusion or not in the study. The remaining inclusion and exclusion criteria must be fulfilled. A written report will be established.
Exclusion Criteria :
- Age ≥ 18 years
- Patients previously treated with Anti-Thymoglobulin (SAL), etoposide (VP16) or Alemtuzumab.
- Confirmed or suspected diagnosis of a malignant or rheumatic disease
Contraindication (s) to the administration of Alemtuzumab :
- Hypersensitivity to murine proteins or to any of the excipients (sodium chloride, dibasic sodium phosphate, potassium chloride, potassium dihydrogen phosphate, polysorbate 80, disodium edetate dihydrate, and water for injection)
- General evolving infection except infections that are the triggering factor of the HLH .
- HIV
- Progressing malignant tumors
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: hemophagocytic lymphohistiocytosis (HLH)
Alemtuzumab (CAMPATH®)
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of surviving patients until HSCT
Time Frame: Day 1 until transplantation, up to 4 months
|
Day 1 until transplantation, up to 4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of complete remissions following treatment
Time Frame: Day 14, Day 21, Day 28
|
To assess the efficacy of the Alemtuzumab
|
Day 14, Day 21, Day 28
|
Time of delay between the first administration of Alemtuzumab and complete remission
Time Frame: Day 14, Day 21, Day 28
|
To assess the efficacy of the Alemtuzumab
|
Day 14, Day 21, Day 28
|
Dosage of Alemtuzumab
Time Frame: Day1-3, Day7, Day15-16, Day22-23, Day28
|
Pharmacokinetic
|
Day1-3, Day7, Day15-16, Day22-23, Day28
|
Number of side effects
Time Frame: Day 1 until transplantation, up to 4 months
|
To assess the tolerance of the Alemtuzumab
|
Day 1 until transplantation, up to 4 months
|
Collaborators and Investigators
Investigators
- Study Director: Alain Fischer, MD, PhD, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Lymphatic Diseases
- Histiocytosis, Non-Langerhans-Cell
- Histiocytosis
- Lymphohistiocytosis, Hemophagocytic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Antineoplastic Agents, Immunological
- Dermatologic Agents
- Antifungal Agents
- Calcineurin Inhibitors
- Prednisolone
- Methylprednisolone Acetate
- Methylprednisolone
- Methylprednisolone Hemisuccinate
- Prednisolone acetate
- Prednisolone hemisuccinate
- Prednisolone phosphate
- Cyclosporine
- Cyclosporins
- Alemtuzumab
Other Study ID Numbers
- P120109
- 2014-005585-30 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemophagocytic Lymphohistiocytosis (HLH)
-
Gunnar LachmannCompletedHemophagocytic Lymphohistiocytosis (HLH) | Macrophage Activation Syndrome (MAS) | Hemophagocytic Syndromes
-
Meir Medical CenterRabin Medical Center; Children's Hospital Medical Center, Cincinnati; Sheba Medical... and other collaboratorsRecruitingHematologic Neoplasms | Hematologic Malignancy | Hemophagocytic Syndrome | Hemophagocytic Lymphohistiocytoses | HLHIsrael
-
The First Affiliated Hospital with Nanjing Medical...Unknown
-
Children's Hospital Medical Center, CincinnatiBaylor College of Medicine; Sobi, Inc.RecruitingHemophagocytic LymphohistiocytosesUnited States
-
Swedish Orphan BiovitrumLight Chain Bioscience - Novimmune SATerminatedHemophagocytic LymphohistiocytosesUnited States
-
Swedish Orphan BiovitrumHarvard Medical School (HMS and HSDM); Brigham and Women's HospitalCompletedHemophagocytic LymphohistiocytosesUnited States
-
University of California, San FranciscoIncyte CorporationNot yet recruitingRuxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)Hemophagocytic LymphohistiocytosesUnited States
-
Beijing Friendship HospitalNot yet recruitingEBV | Hemophagocytic Lymphohistiocytoses | MetabonomicsChina
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...CompletedAcute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia | Hemophagocytic Lymphohistiocytosis (HLH) | Non Hodgkins Lymphoma | Familial Hemophagocytic Lymphohistiocytosis (FLH) | Viral-associated Hemophagocytic Syndrome (VAHS) | X-linked Lymphoproliferative...United States
-
Beijing Friendship HospitalRecruitingHemophagocytic LymphohistiocytosisChina
Clinical Trials on Alemtuzumab
-
German CLL Study GroupCompletedChronic Lymphocytic LeukemiaGermany
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI); Genzyme, a Sanofi CompanyCompleted
-
Genzyme, a Sanofi CompanyTerminatedNon-Hodgkins LymphomaUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnLymphomaUnited States, Australia, United Kingdom, Canada, France
-
Karolinska University HospitalSchering Nordiska ABCompleted
-
Latin American Cooperative Onco-Haematology Group...UnknownMycosis Fungoides | Sezary SyndromePeru
-
Genzyme, a Sanofi CompanyTerminatedHematologic MalignanciesUnited States
-
Genzyme, a Sanofi CompanyCompletedB Cell Chronic Lymphocytic LeukemiaUnited States
-
German CLL Study GroupCompleted
-
University Hospital MuensterUnknown